Hashem Haghdoost-Yazdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hashem Haghdoost-Yazdi has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Ayda Faraji
A Cellular and Molecular Research Center , Qazvin University of Medical Sciences , Qazvin , Iran
6 shared publicationsNafiseh Rastgoo
Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
5 shared publicationsNegin Fraidouni
Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
5 shared publicationsAli Sarbazi-Golezari
Cellular and Molecular Research Center, Research Institute for prevention of Non- Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
3 shared publicationsAzita Minaei
Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
3 shared publicationsGila Behzadi
3 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by InkVista Publishing House in Physiology and Pharmacology
- Vol. 29 (4) , 375-385
Serum levels of thyroid hormones change differently in the onset and progress phases of the experimental model of Parkinson’s disease in rats
Introduction: Changes in the levels of serum components can help in the early and differential diagnosis of Parkinson’s disease (PD). The lesion in the dopaminergic (DAergic) system is the main pathophysiological mechanism underlying PD. This system is closely related to the hypothalamic-pituitary-thyroid axis. Here, we examined the impact of PD ...
- 1 December 2025
- Published by InkVista Publishing House in Physiology and Pharmacology
- Vol. 29 (4) , 375-385
Open AccessSerum levels of thyroid hormones change differently in the onset and progress phases of the experimental model of Parkinson’s disease in rats
Introduction: Changes in the levels of serum components can help in the early and differential diagnosis of Parkinson’s disease (PD). The lesion in the dopaminergic (DAergic) system is the main pathophysiological mechanism underlying PD. This system is closely related to the hypothalamic-pituitary-thyroid axis. Here, we examined the impact of PD ...
- Retraction
- 29 May 2024
- Published by Springer Nature in Biological Trace Element Research
- Vol. 203 (3) , 1788
Retraction Note: Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson’s Disease
- 29 May 2024
- Published by Springer Nature in Biological Trace Element Research
- Vol. 203 (3) , 1788
RetractionRetraction Note: Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson’s Disease
- 13 May 2024
- Published by Taylor & Francis in Neurological Research
- Vol. 46 (8) , 763-771
Dexmedetomidine, an alpha-2 adrenoceptors agonist, provides a neuroprotective effect for dopaminergic neurons in the substantia nigra and attenuates glucose imbalance in the 6-hydroxydopamine animal model of Parkinson’s disease
IntroductionStudies have shown that dexmedetomidine (DEX, an a2-adrenoceptors agonist) provides a neuroprotective effect and influences blood glucose levels. Here, we evaluated the effect of prolonged treatment with low doses of DEX on the survival rate of dopaminergic (DAergic) neurons in the substantia nigra and also serum glucose levels in 6-hydroxydopamine (6-OHDA) - induced Parkinson's disease (PD) in the rat.Material and MethodsThe neurotoxin of 6-OHDA was injected into the medial forebrain bundle by stereotaxic surgery. DEX (25 and 50 mu g/kg, i.p) and yohimbine, an a2-adrenoceptor antagonist (1 mg/kg, i.p) were administered before the surgery to the 13 weeks afterward. Apomorphine-induced rotational tests and blood sampling were carried out before the surgery and multiple weeks after that. Thirteen weeks after the surgery, the rats' brain was transcardially perfused to assess the survival rate of DAergic neurons using the tyrosine hydroxylase (TH) immunohistochemistry.ResultsDEX remarkably attenuated the severity of rotational behavior and reversed the progress of the PD. It also increased the number of TH-labeled neurons by up to 60%. The serum glucose levels in 6-OHDA-received rats did not change in the third and seventh weeks after the surgery but decreased significantly in the thirteenth week. Treatment with DEX prevented this decrement in glucose levels. On the other hand, Treatment with yohimbine did not affect PD symptoms and glucose levels.ConclusionOur data indicate that DEX through neuroprotective activity attenuates the severity of 6-OHDA-induced PD in rats. DEX might also prevent hypoglycemia during the progress of the PD.
- 13 May 2024
- Published by Taylor & Francis in Neurological Research
- Vol. 46 (8) , 763-771
Dexmedetomidine, an alpha-2 adrenoceptors agonist, provides a neuroprotective effect for dopaminergic neurons in the substantia nigra and attenuates glucose imbalance in the 6-hydroxydopamine animal model of Parkinson’s disease
IntroductionStudies have shown that dexmedetomidine (DEX, an a2-adrenoceptors agonist) provides a neuroprotective effect and influences blood glucose levels. Here, we evaluated the effect of prolonged treatment with low doses of DEX on the survival rate of dopaminergic (DAergic) neurons in the substantia nigra and also serum glucose levels in 6-hydroxydopamine (6-OHDA) - induced Parkinson's disease (PD) in the rat.Material and MethodsThe neurotoxin of 6-OHDA was injected into the medial forebrain bundle by stereotaxic surgery. DEX (25 and 50 mu g/kg, i.p) and yohimbine, an a2-adrenoceptor antagonist (1 mg/kg, i.p) were administered before the surgery to the 13 weeks afterward. Apomorphine-induced rotational tests and blood sampling were carried out before the surgery and multiple weeks after that. Thirteen weeks after the surgery, the rats' brain was transcardially perfused to assess the survival rate of DAergic neurons using the tyrosine hydroxylase (TH) immunohistochemistry.ResultsDEX remarkably attenuated the severity of rotational behavior and reversed the progress of the PD. It also increased the number of TH-labeled neurons by up to 60%. The serum glucose levels in 6-OHDA-received rats did not change in the third and seventh weeks after the surgery but decreased significantly in the thirteenth week. Treatment with DEX prevented this decrement in glucose levels. On the other hand, Treatment with yohimbine did not affect PD symptoms and glucose levels.ConclusionOur data indicate that DEX through neuroprotective activity attenuates the severity of 6-OHDA-induced PD in rats. DEX might also prevent hypoglycemia during the progress of the PD.
- RetractionOpen Access
- 26 September 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (3) , 483
Retraction Note: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
- 26 September 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (3) , 483
RetractionOpen AccessRetraction Note: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
- Open Access
- 1 December 2022
- Published by CMV Verlag in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 27 (5) , 10-23
Increased Serum Lithium Level due to Mild to Moderate damage to Dopaminergic Neurons of the Substantia Nigra, Evidence from Animal Model of Parkinson’s Disease induced by 6-Hydoxydopamine
Background and Aim. It has been reported that lithium (Li) has neuroprotective effects in neurodegenerative diseases. In this study, we investigated the association between serum Li level and Parkinson’s disease induced by 6-hydroxypapamine (6-OHDA) in rats. Material and Methods. 6-OHDA was injected into the medial forebrain bundle by stereotoxic surgery. ...
- 1 December 2022
- Published by CMV Verlag in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 27 (5) , 10-23
Open AccessIncreased Serum Lithium Level due to Mild to Moderate damage to Dopaminergic Neurons of the Substantia Nigra, Evidence from Animal Model of Parkinson’s Disease induced by 6-Hydoxydopamine
Background and Aim. It has been reported that lithium (Li) has neuroprotective effects in neurodegenerative diseases. In this study, we investigated the association between serum Li level and Parkinson’s disease induced by 6-hydroxypapamine (6-OHDA) in rats. Material and Methods. 6-OHDA was injected into the medial forebrain bundle by stereotoxic surgery. ...
- 5 January 2022
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (6) , 544-553
Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-α and IL-1β; evidence from early experimental model of Parkinson’s disease
Studies have shown that inflammation plays a key role in etiology of Parkinson’s disease (PD). However, human studies which have evaluated association between PD and serum levels of tumor necrosis ...
- 5 January 2022
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (6) , 544-553
Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-α and IL-1β; evidence from early experimental model of Parkinson’s disease
Studies have shown that inflammation plays a key role in etiology of Parkinson’s disease (PD). However, human studies which have evaluated association between PD and serum levels of tumor necrosis ...
- Retracted
- 12 November 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 37 (2) , 373-381
RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.
- 12 November 2021
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 37 (2) , 373-381
RetractedRETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.
- Retracted
- 6 November 2021
- Published by Springer Nature in Biological Trace Element Research
- Vol. 200 (9) , 4058-4067
RETRACTED ARTICLE: Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson’s Disease
Mild to moderate dopaminergic (DA) neuronal death in substantia nigra pars compacta (SNc) as the main pathological hallmark of Parkinson’s disease (PD) is usually silent and does not produce marked clinical symptoms. In this study, we investigated the association between SNc DA neuronal loss and serum levels of total bilirubin (TB), selenium (Se), and zinc (Zn) in 6-hydroxydopamine (6-OHDA) animal model of PD. The neurotoxin of 6-OHDA was injected into the medial forebrain bundle of right hemisphere by stereotaxic surgery. Two conventional behavioral tests were carried out in several steps after the toxin to confirm the model reproduction and quantify severity and progress of 6-OHDA-induced PD. Blood samples were collected within 1 week before the toxin and in the second, fifth, and eighth weeks thereafter. Immunohistochemistry (IHC) assessments were performed on the rat’s brain to determine the severity of DA neuronal loss in SNc. The severity of behavioral symptoms and TB levels were progressively increased in 6-OHDA-treated rats. On the other hand, Se and Zn levels in them were lower than control. These changes were observed in rats with severe or mild behavioral symptoms. Also, IHC revealed that changes in TB, Se, and Zn associate with SNc DA neuronal loss but do not correlate with its severity. Significant changes in serum levels of TB, Se, and Zn in the mild SNc DA neuronal loss suggest them as valuable parameters for establishment of a serum profile for early detection of PD.
- 6 November 2021
- Published by Springer Nature in Biological Trace Element Research
- Vol. 200 (9) , 4058-4067
RetractedRETRACTED ARTICLE: Dopaminergic Neuronal Death in Substantia Nigra Associates with Serum Levels of Total Bilirubin, Selenium, and Zinc: Evidences from 6-Hydroxydopamine Animal Model of Parkinson’s Disease
Mild to moderate dopaminergic (DA) neuronal death in substantia nigra pars compacta (SNc) as the main pathological hallmark of Parkinson’s disease (PD) is usually silent and does not produce marked clinical symptoms. In this study, we investigated the association between SNc DA neuronal loss and serum levels of total bilirubin (TB), selenium (Se), and zinc (Zn) in 6-hydroxydopamine (6-OHDA) animal model of PD. The neurotoxin of 6-OHDA was injected into the medial forebrain bundle of right hemisphere by stereotaxic surgery. Two conventional behavioral tests were carried out in several steps after the toxin to confirm the model reproduction and quantify severity and progress of 6-OHDA-induced PD. Blood samples were collected within 1 week before the toxin and in the second, fifth, and eighth weeks thereafter. Immunohistochemistry (IHC) assessments were performed on the rat’s brain to determine the severity of DA neuronal loss in SNc. The severity of behavioral symptoms and TB levels were progressively increased in 6-OHDA-treated rats. On the other hand, Se and Zn levels in them were lower than control. These changes were observed in rats with severe or mild behavioral symptoms. Also, IHC revealed that changes in TB, Se, and Zn associate with SNc DA neuronal loss but do not correlate with its severity. Significant changes in serum levels of TB, Se, and Zn in the mild SNc DA neuronal loss suggest them as valuable parameters for establishment of a serum profile for early detection of PD.
- Open Access
- 1 July 2021
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 12 (4) , 453-464
Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine- Induced Parkinsonism in Male Rats
Introduction: Parkinson’s Disease (PD) associates with changes in sex hormones; however, it remains unknown whether this is either a cause for or a result of the disease. To further evaluate it, we investigated if the development of 6-Hydroxydopamine (6-OHDA)-induced Parkinsonism changes the serum levels of testosterone and prolactin or not. Methods: 6-OHDA was injected into the medial forebrain bundle using stereotaxic surgery. The development of Parkinsonism was evaluated by apomorphine-induced rotational test and the immunofluorescence labeling of Dopaminergic (DA) neurons in substantia nigra. The necessary blood samples were collected before the toxin and in the third and sixth weeks afterward. The hormones levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA) kits. Results: The severity of rotations was different among 6-OHDA-treated rats; accordingly, they were divided into two subgroups of severe and mild parkinsonian rats. The degeneration of DA neurons was observed in both subgroups; however, it was significantly less in the mild group. In the sixth week after the toxin, testosterone level increased but only in the severe subgroup. Prolactin increased in both subgroups in the third week after the toxin but returned to normal in the sixth week. There was no association between the pre-toxin levels of these hormones and the intensity of Parkinsonism. Conclusion: Our findings indicated that the development of 6-OHDA-induced Parkinsonism increases the serum levels of testosterone and prolactin. Increased prolactin occurred earlier and was observed in rats with less DA neuronal loss. Therefore, prolactin levels can predict the death of DA neurons before the clinical signs of PD were revealed.
- 1 July 2021
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 12 (4) , 453-464
Open AccessEvaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine- Induced Parkinsonism in Male Rats
Introduction: Parkinson’s Disease (PD) associates with changes in sex hormones; however, it remains unknown whether this is either a cause for or a result of the disease. To further evaluate it, we investigated if the development of 6-Hydroxydopamine (6-OHDA)-induced Parkinsonism changes the serum levels of testosterone and prolactin or not. Methods: 6-OHDA was injected into the medial forebrain bundle using stereotaxic surgery. The development of Parkinsonism was evaluated by apomorphine-induced rotational test and the immunofluorescence labeling of Dopaminergic (DA) neurons in substantia nigra. The necessary blood samples were collected before the toxin and in the third and sixth weeks afterward. The hormones levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA) kits. Results: The severity of rotations was different among 6-OHDA-treated rats; accordingly, they were divided into two subgroups of severe and mild parkinsonian rats. The degeneration of DA neurons was observed in both subgroups; however, it was significantly less in the mild group. In the sixth week after the toxin, testosterone level increased but only in the severe subgroup. Prolactin increased in both subgroups in the third week after the toxin but returned to normal in the sixth week. There was no association between the pre-toxin levels of these hormones and the intensity of Parkinsonism. Conclusion: Our findings indicated that the development of 6-OHDA-induced Parkinsonism increases the serum levels of testosterone and prolactin. Increased prolactin occurred earlier and was observed in rats with less DA neuronal loss. Therefore, prolactin levels can predict the death of DA neurons before the clinical signs of PD were revealed.